Ken Griffin Cogent Biosciences, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 27,800 shares of COGT stock, worth $231,296. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,800

Previous 46,500 40.22%

Holding current value

$231,296

Previous $273,000 31.87%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.38 - $9.02 $2.23 Million - $4.59 Million	-508,880 Reduced 79.42%	131,891 $886,000
Q4 2023 Feb 14, 2024	BUY	$4.06 - $10.08 $2.36 Million - $5.85 Million	580,166 Added 957.29%	640,771 $3.77 Million
Q3 2023 Nov 14, 2023	SELL	$9.69 - $13.34 $718,629 - $989,321	-74,162 Reduced 55.03%	60,605 $590,000
Q2 2023 Aug 14, 2023	SELL	$9.85 - $13.24 $11.4 Million - $15.4 Million	-1,161,005 Reduced 89.6%	134,767 $1.6 Million
Q1 2023 May 15, 2023	SELL	$10.04 - $15.5 $5.61 Million - $8.66 Million	-558,548 Reduced 30.12%	1,295,772 $14 Million

Q4 2022 Feb 14, 2023	BUY	$10.65 - $14.84 $5.56 Million - $7.75 Million	522,040 Added 39.18%	1,854,320 $21.4 Million
Q3 2022 Nov 14, 2022	BUY	$9.39 - $16.99 $2.45 Million - $4.43 Million	260,766 Added 24.34%	1,332,280 $19.9 Million
Q2 2022 Aug 15, 2022	BUY	$3.92 - $9.73 $3.94 Million - $9.79 Million	1,006,013 Added 1535.87%	1,071,514 $9.67 Million
Q1 2022 May 16, 2022	BUY	$5.31 - $8.7 $271,664 - $445,100	51,161 Added 356.77%	65,501 $491,000
Q3 2021 Nov 15, 2021	SELL	$5.99 - $9.14 $7.72 Million - $11.8 Million	-1,289,319 Reduced 98.9%	14,340 $121,000
Q1 2021 May 17, 2021	BUY	$7.47 - $12.34 $3.34 Million - $5.51 Million	446,717 Added 52.13%	1,303,659 $11.1 Million
Q4 2020 Feb 16, 2021	BUY	$9.04 - $13.01 $7.75 Million - $11.1 Million	856,942 New	856,942 $9.62 Million

Others Institutions Holding COGT

# of Institutions

159

Shares Held

102M

Call Options Held

197K

Put Options Held

102K

View Full List

About Cogent Biosciences, Inc.

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $547M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

More about COGT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account